Attorney Docket No.

Country

United States Of America

BRYAN C. ZIELINSKI

NAME (Print/type)

Signature

Telephone

(212)573-2369

Registration No. (Attorney/Agent)

Date

ease type a plus sign (+) inside this box ->		
	-	
ease type a plus sign (+) inside this box -> I		

PTO/SB/05 (2/8)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

## UTILITY PATENT APPLICATION TRANSMITTAL

First Named Inventor or Application Identifier J. C. KATH

Title SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT
OF ABNORMAL CELL GROWTH

PC 10760A

Express Mail Lahel No. EL162814382US Only for new nonprovisional applications under 37C F.R. \$1,53(b); APPLICATION FLEMENTS ADDRESS TO: Box Patent Application وي See MPEP chapter 600 concerning utility patent application contents Washington, DC 20231 \*Fee Transmittal Form (e.g., PTO/SB/17) 6 Microfiche Computer Program (Appendix) Nucleotide and/or Amino Acid Sequence Submission -œ 7. 2. Specification ITotal Pages 84 (preferred arrangement set forth below) - Descriptive title of the Invention Computer Readable Copy Cross References to Related Applications Paper Copy (identical to computer copy) Statement Regarding Fed sponsored R&D h - Reference in Microfiche Appendix Statement verifying identity of above copies - Background of the Invention ACCOMPANYING APPLICATION PARTS Brief Summary of the Invention 8. Assignment Papers (cover sheet & document(s)) Brief Description of the Drawings (if filed) Detailed Description 37 C F.R. §3,73(b) Statement Power of Attorney Claim(e) (when there is an assignee) Abstract of the Disclosure 10 English Translation Document (if applicable) Information Disclosure Copies of IDS Drawing(s) (35 U.S.C. 11.3)[Total sheets Statement (IDS)/PTO-1449 Citations Oath or Declaration [Total pages 12 Preliminary Amendment Newly executed (original or copy) 13 Return Receipt Postcard (MPEP 503) (Should be specifically itemized) Copy from a prior application (37 CFR §1.63(d)) Statement filed in prior application. (for continuation/divisional with Box 17 completed) Statement(s) Status still proper and desired [Note Box 5 below] (PTO/SB/09-12) DELETION OF INVENTOR(S) 15 Certified Copy of Priority Document(s) Signed statement attached deleting (if foreign priority is claimed) inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b). Priority Claim - APPLICANTS CLAIM Incorporation By Reference (useable if Box 4b is checked) Other PRIORITY FROM U.S. PROVISIONAL NO. The entire disclosure of the prior application, from which a 60/213136, FILED JUNE 20, 2000 copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein. NOTE FOR ITEMS 1.8.14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STREMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28). If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment Continuation Divisional Continuation-in-part (CIP) of prior application No: Group/Art Unit: Prior application information: Examiner 18 CORRESPONDENCE ADDRESS (Insert Customer No. or Attach bar code label here) Customer Number or Bar Code Label Correspondence address below Paul H. Ginsburg Name Address Pfizer Inc Address 235 East 42nd Street, 20th Floor City New York State New York Zip Code 10017-5755

34.462

(212)573-1939

JUNE 18, 2001

Fav

PTO/SB/17(2/9)

Approved for use through 09/303/2000 OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Complete if Known FEE TRANSMITTAL Application Number N/A Filing Date June 18, 2001 Patent fees are subject to annual revision on October 1 First Named Inventor J. C. KATH These are the fees effective October 1, 1997 Examiner Name Small Entity payments must be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12. Group/Art Unit N//A See 37 C.F.R. §§ 1.27 and 1.28 Total Amount of Payment (\$)728 Attorney Docket No PC 10760A METHOD OF PAYMENT (check one) FEE CALCULATION (continued 3. ADDITIONAL FEES The commissioner is hereby authorized to charge 1. [X] indicated fees and credit any over navments to: Large Entity Small Entity Fee Deposit Account Number Fee Fee Code Code (\$) Fee Description Danneit 120 205 Sumbarge - late fee or noth 105 85 Account PFIZER INC 50 227 25 Surcharge-late provisional filing fee or 127 cover sheet Charge Any Additional Fee Required Under Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Malling of the Notice of Allowance. Non-English specification 139 130 139 130 37 C F.R. §§ 1.16 and 1.17. 147 2 520 147 2 520 For filling a request for reexamination 9201 112 920\* Requesting publication of SIR prior to Payment Enclosed: Examiner action
Requesting publication of SIR after 1 8401 Money Order Other 113 1 8401 113 Check Examiner action FEE CALCULATION 110 215 55 Extension for reply within first month 1. BASIC FILING FEE 390 216 195 Extension for reply within second 14 890 217 446 Extension for reply within third month Entity Smal Entity Fee Fee Description Fee Paid 1,390 218 Extension for reply within fourth month Fee 118 695 UT Code (\$) Code (\$3 N 1.890 Extension for reply within fifth month 128 228 945 101 710 201 355 Utility filing fee 710 119 310 219 155 Notice of Appeal 106 320 208 160 Design filing fee 7 120 310 220 155 Filing a brief in support of an appeal 107 490 207 245 Plant filing fee 121 270 221 135 Request for oral heaning 356 Reissue filing fee 108 710 208 Đ. 138 1.510 138 1.510 Petition to institute a public use 214 75 Provisional filing fee 114 150 proceeding 710 SUBTOTAL (1) (\$) 140 110 240 55 Petition to revive - unavoidable 2. EXTRA CLAIM FEES 141 1,240 241 620 Petition to revive - unintentional 620 Utility issue fee (or reissue) Extra Fee from 142 1 240 242 Fee Paid Claims Total Claims 21 18 143 440 243 220 Design issue fee 18 144 800 244 300 Plant issue fee Independent 1 n 122 130 122 130 Petitions to the Commissioner Multiple Dependent 0 \*\* or number previously paid if greater: For Reissues, see helow 123 50 123 50 Petitions related to provisional Small Entity Large Entity annlications Fee Description 128 240 126 240 Submission of Information Disclosure Code (\$) Code (\$) Statement 40 103 203 Claims in excess of 20 581 40 Recording each patent assignment per property (times number of properties) 102 ลก 202 40 Independent claims in excess of 3 146 710 246 355 Filing a submission after final rejection (37 CFR 1.129(a)) 270 204 135 Multiple dependent claim, if not paid 710 249 355 For each additional invention to be 104 examined (37 CFR 1.129(b)) 109 80 209 40 \*\*Reissue independent claims over Other Fee (specify) original natent 110 210 Reissue claims in excess of 20 and Other Fee (specify) over original patent SUBTOTAL (2) (\$) \*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 7 SUBMITTED BY Complete (if Applicable) Type or Printed Name BRYAN C. ZIELINSK Reg. Number Deposit Account Signature JUNE 18 2001 16-1445

User ID